reports
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics Announces Pricing of $250 Million Public Offering WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common...
Kymera Therapeutics Announces Proposed Public Offering
Kymera Therapeutics Announces Proposed Public Offering WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offer...
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical c...
EY US announces Rohit Kapoor of EXL as an Entrepreneur Of The Year® 20...
EY US announces Rohit Kapoor of EXL as an Entrepreneur Of The Year® 2025 New York Award winner Celebrating the bold leaders shaping the future through the world’s most ground-breaking companies NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) announced that Rohit Kapoor, chairman and chief executive officer of EXL, was named an Entrepreneur Of The Year 2025 New York Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US has celebrated ambitious entrepreneurs who ...
Seneca Foods Reports Sales and Earnings for the Quarter and Twelve Mon...
Seneca Foods Reports Sales and Earnings for the Quarter and Twelve Months Ended March 31, 2025 FAIRPORT, N.Y., June 12, 2025 (GLOBE NEWSWIRE) -- Seneca Foods Corporation (NASDAQ: SENEA, SENEB) today announced financial results for the fourth quarter and twelve months ended March 31, 2025. Executive Summary (vs. year-ago, year-to-date results): Net sales for the twelve months ended March 31, 2025 totaled $1,578.9 million compared to $1,458.6 million for the twelve months ended March 31, 2024. The year-over-year increase of $120.3 million was driven by higher sales volumes, complemented b...
Operating Results Improvements Continue at Hooker Furnishings in Q1
Operating Results Improvements Continue at Hooker Furnishings in Q1 Driven by Stable Legacy Sales and Ongoing Cost Savings Initiatives MARTINSVILLE, Va., June 12, 2025 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (the “Company” or “HFC”), a global leader in the design, production, and marketing of home furnishings for 101 years, today reported its operating results for its fiscal 2026 first quarter ended May 4, 2025. Key Results for the Fiscal 2026 First Quarter: The Company lowered its operating loss by $1.6 million, or 31%, from the prior year...
Hooker Furnishings Declares Quarterly Dividend
Hooker Furnishings Declares Quarterly Dividend MARTINSVILLE, Va., June 04, 2025 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (Nasdaq-GS: HOFT) announced that on June 3, 2025, its board of directors declared a quarterly cash dividend of $0.23 per share, payable on June 30, 2025, to shareholders of record on June 16, 2025. Hooker Furnishings Corporation, in its 101st year of business, is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home décor for the residential, hospitality an...
EXL achieves the AWS Generative AI Competency
EXL achieves the AWS Generative AI Competency EXL expands its digital reach with five innovative solutions now available in AWS Marketplace, empowering business to unlock faster, smarter, data and AI-driven transformation NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading data and AI company, announced it has achieved the Amazon Web Services (AWS) Generative AI Competency within the AWS Partner Network (APN). The designation recognizes EXL as a trusted AWS Partner with deep domain expertise and proven success in delivering generative AI (GenAI) solutions, position...
Kymera Therapeutics Announces Positive First-in-Human Results from Pha...
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC...
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial...
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To...
EXL partners with Databricks to launch Gen-AI powered code migration a...
EXL partners with Databricks to launch Gen-AI powered code migration accelerator EXL Code Harbor™ solution speeds code migration from SAS to Databricks with up to 80% reduction in manual effort NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading data and AI company, expanded its partnership with Databricks, the data and AI company, to deploy a GenAI-enabled SAS to Databricks Data Intelligence Platform migration solution. Leveraging EXL’s Code Harbor™ solution, the solution helps enterprises streamline their transition from SAS to Databricks to support enhanced cloud...
Kymera Therapeutics to Participate in Upcoming June Investor Conferenc...
Kymera Therapeutics to Participate in Upcoming June Investor Conferences WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Jefferies Global Healthcare Conference in New York, NY on June 5 at 8:10 a.m. ET;Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on June 10 at 3:20 p.m. ET; andWolfe Research Virtual B...
Hooker Furnishings to Host First Quarter Earnings Call June 12th
Hooker Furnishings to Host First Quarter Earnings Call June 12th MARTINSVILLE, Va., May 29, 2025 (GLOBE NEWSWIRE) -- Hooker Furnishings Corporation (Nasdaq-GS: HOFT) will present its fiscal 2026 first quarter financial results via teleconference and live internet web cast on Thursday morning, June 12, 2025 at 9:00 AM Eastern Time. A live webcast of the call will be available on the Investor Relations page of the Company’s website at and archived for replay. To access the call by phone, participants should go to this link ) and you will be provided with dial-in details. To avoid delays, ...
UK businesses race to embed AI into enterprise workflows, EXL study fi...
UK businesses race to embed AI into enterprise workflows, EXL study finds Three-quarters of companies believe they have an edge on their competition, but many worry siloed data and talent shortages could impede their AI progress LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Businesses in the UK are making significant changes in the ways they work as they increasingly embed AI throughout their workflows and to scale and maximise ROI, according to new research by EXL [NASDAQ: EXLS], a global data and AI company. An 86% majority of organisations have significantly changed their operating model ...
EXL named Microsoft Solutions Partner for Data and AI
EXL named Microsoft Solutions Partner for Data and AI Designation underscores EXL’s digital innovation and proven success delivering data and AI solutions for global clients NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading data and AI company, announced it has been recognized as a Microsoft Solutions Partner for Data and AI. This designation acknowledges EXL’s advanced capabilities in helping clients manage data across systems and build transformative analytics and AI solutions on Microsoft platforms. This designation highlights EXL’s technology capabilities, hi...
Organizations race to embed AI into enterprise workflows, EXL study fi...
Organizations race to embed AI into enterprise workflows, EXL study finds Three-quarters of companies believe they have an edge on their competition, but many worry siloed data and talent shortages could impede their AI progress NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Organizations are changing the ways they work, sometimes radically, to embed AI throughout their workflows and to scale and maximize ROI, according to new research by EXL [NASDAQ: EXLS], a global data and AI company. A 90% majority of organizations have significantly changed their operating model to accommodate AI, with...
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-...
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with data to be reported in June 2025 KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) ongoing with data expected in 4Q25 Two parallel Phase 2b trials in AD and ...
EXL named a Leader in 2025 Gartner® Magic Quadrant™ for Finance and Ac...
EXL named a Leader in 2025 Gartner® Magic Quadrant™ for Finance and Accounting Business Process Outsourcing NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, has been named a Leader in the 2025 Gartner Magic Quadrant for Finance and Accounting (F&A) Business Process Outsourcing (BPO). The Gartner research report evaluated 16 F&A service providers according to a uniform set of criteria, placing companies into four Quadrants: Leaders, Visionaries, Niche Players and Challengers. Gartner defines Leaders as companies that “execute well against thei...
ExlService Holdings Inc: 1 director
A director at ExlService Holdings Inc sold 25,000 shares at 46.110USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with ...
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, ora...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.